PURPOSE: The number of patients with cancer enrolling in phase I trials is expected to increase as these trials incorporate patient selection and exhibit greater efficacy in the era of targeted therapies. Despite the fact that people with advanced cancer often require a caregiver, little is known about the experience of caregivers of people enrolling in oncology phase I clinical trials. We conducted a cross-sectional study assessing the distress and emotion regulation of caregivers of phase I trial participants to inform the design of future interventions targeting the unique needs of this population. METHODS: Caregivers of oncology patients were approached at the patient's phase I clinical trial screening visit. Caregiver participants completed a one-time survey incorporating validated instruments to comprehensively assess distress and emotion regulation. Basic demographic information about both the caregiver and patient was collected. RESULTS: Caregivers exhibited greater distress than population norms. Emotion regulation was also moderately impaired. Respondents identified positive aspects of caregiving despite exhibiting moderate distress. CONCLUSION: Enrollment of a patient in a phase I clinical trial is a time of stress for their caregivers. This pilot study demonstrates the feasibility of engaging caregivers of phase I trial participants and the need to better support them through this component of their caregiving experience.
PURPOSE: The number of patients with cancer enrolling in phase I trials is expected to increase as these trials incorporate patient selection and exhibit greater efficacy in the era of targeted therapies. Despite the fact that people with advanced cancer often require a caregiver, little is known about the experience of caregivers of people enrolling in oncology phase I clinical trials. We conducted a cross-sectional study assessing the distress and emotion regulation of caregivers of phase I trial participants to inform the design of future interventions targeting the unique needs of this population. METHODS: Caregivers of oncology patients were approached at the patient's phase I clinical trial screening visit. Caregiver participants completed a one-time survey incorporating validated instruments to comprehensively assess distress and emotion regulation. Basic demographic information about both the caregiver and patient was collected. RESULTS: Caregivers exhibited greater distress than population norms. Emotion regulation was also moderately impaired. Respondents identified positive aspects of caregiving despite exhibiting moderate distress. CONCLUSION: Enrollment of a patient in a phase I clinical trial is a time of stress for their caregivers. This pilot study demonstrates the feasibility of engaging caregivers of phase I trial participants and the need to better support them through this component of their caregiving experience.
Authors: Pamela H Mitchell; Lynda Powell; James Blumenthal; Jennifer Norten; Gail Ironson; Carol Rogers Pitula; Erika Sivarajan Froelicher; Susan Czajkowski; Marston Youngblood; Marc Huber; Lisa F Berkman Journal: J Cardiopulm Rehabil Date: 2003 Nov-Dec Impact factor: 2.081
Authors: C Nijboer; R Tempelaar; R Sanderman; M Triemstra; R J Spruijt; G A van den Bos Journal: Psychooncology Date: 1998 Jan-Feb Impact factor: 3.894
Authors: Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245
Authors: K E Covinsky; L Goldman; E F Cook; R Oye; N Desbiens; D Reding; W Fulkerson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1994-12-21 Impact factor: 56.272
Authors: Eva Grunfeld; Doug Coyle; Timothy Whelan; Jennifer Clinch; Leonard Reyno; Craig C Earle; Andrew Willan; Raymond Viola; Marjorie Coristine; Teresa Janz; Robert Glossop Journal: CMAJ Date: 2004-06-08 Impact factor: 8.262
Authors: Crystal Natvig; Susan K Mikulich-Gilbertson; Mark L Laudenslager; Cathy J Bradley Journal: J Cancer Surviv Date: 2021-08-21 Impact factor: 4.062
Authors: M L Laudenslager; T L Simoneau; K Kilbourn; C Natvig; S Philips; J Spradley; P Benitez; P McSweeney; S K Mikulich-Gilbertson Journal: Bone Marrow Transplant Date: 2015-05-11 Impact factor: 5.483